Senotherapeutics: a possible mitigator of age-related pulmonary disease

Editorial

eBioMedicine. EBioMedicine. 2023 Oct.

. 2023 Oct:96:104837.

doi: 10.1016/j.ebiom.2023.104837.

No abstract available

Comment on

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability.
Nambiar A, Kellogg D 3rd, Justice J, Goros M, Gelfond J, Pascual R, Hashmi S, Masternak M, Prata L, LeBrasseur N, Limper A, Kritchevsky S, Musi N, Tchkonia T, Kirkland J. Nambiar A, et al. EBioMedicine. 2023 Apr;90:104481. doi: 10.1016/j.ebiom.2023.104481. Epub 2023 Feb 28. EBioMedicine. 2023. PMID: 36857968 Free PMC article. Clinical Trial.